Is Anthem Bioscienc overvalued or undervalued?

As of 29 August 2025, Anthem Bioscienc's valuation grade has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 90.82, a Price to Book Value of 18.59, and an EV to EBITDA of 65.82. These ratios are considerably higher than those of its peers, such as Sun Pharma with a PE of 33.34 and Divi's Lab at 70.28, both of which are categorized as expensive or very expensive.
In comparison to its industry, Anthem Bioscienc's valuation metrics suggest that it is trading at a premium, particularly when considering its PEG ratio of 0.00, which does not provide any growth perspective. While the company has demonstrated strong returns in the past, its current valuation does not align with the fundamentals, making it a candidate for reconsideration by investors. Recent stock performance has shown a slight decline of 0.5% over the past week, contrasting with a more substantial drop in the Sensex of 1.84%, which may indicate some resilience but does not mitigate the overvaluation concern.